Evidence map›Paper›PMID 42701241›Full record

ArticleJournal of the American Chemical Society2026

Catalytic Enantioselective Aziridination of Z-Disubstituted Alkenes with Aspartyl β-Turn-Based Dirhodium(II) Metallopeptides and Assessment of Catalyst Scaffold Versatility.

Melissa Pighetti, Beck R Miller, Annika K Ehrlacher, Matthew S Sigman, Scott J Miller

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melissa PighettiDepartment of Chemistry, Yale University, New Haven, Connecticut06520, United States.ORCID 0000-0001-6558-3006
Beck R MillerDepartment of Chemistry, University of Utah, Salt Lake City, Utah84112, United States.
Annika K EhrlacherDepartment of Chemistry, Yale University, New Haven, Connecticut06520, United States.ORCID 0009-0001-0348-0738
Matthew S SigmanDepartment of Chemistry, University of Utah, Salt Lake City, Utah84112, United States.ORCID 0000-0002-5746-8830
Scott J MillerDepartment of Chemistry, Yale University, New Haven, Connecticut06520, United States.ORCID 0000-0001-7817-1318

Funding

Site-Selective Catalysis for Bioactive Scaffold DiversificationR35GM132092 · NIGMS · YALE UNIVERSITY · PI Scott J Miller · 2019 to 2026
$6.3M
Data Science Guided Organic Reaction DevelopmentR35GM136271 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI MATTHEW S SIGMAN · 2020 to 2026
$3.5M
NIGMS NIH HHS R35 GM132092NIGMS NIH HHS R35 GM136271
6 · The paper itself

Abstract

We report an enantioselective aziridination of open-chain Z-disubstituted alkenes, enabled by a dirhodium(II) metallopeptide featuring finely tuned, β-turn-biased peptidyl ligands. This method affords cis-aziridines in up to 99:1 er and exhibits broad tolerance toward diverse aryl substitution patterns and peripheral functional groups. In conjunction, we explore a data science model that uncovers patterns in molecular features that reflect enantioselectivity across two nitrene transfer reactions catalyzed by dirhodium(II) metallopeptides: the aziridination reported here and a related benzylic amination reaction. This model is trained on molecular descriptors of both catalysts and substrates and used to interpret the differences between the two reactions. By linking a new synthetic methodology to cross-reaction, data science-driven modeling, this study offers both an efficient route to valuable aziridine scaffolds and a framework for analyzing enantioinduction across mechanistically diverse transformations.

Identifiers

PMID42701241
PMCPMC13552212

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.